| Name | Title | Contact Details |
|---|---|---|
Gerrick Rodrigues |
Director Of Information Technology | Profile |
Inspirion Biosciences protects the advancement of science, the safety and security of researchers, and the health of surrounding communities through integrated solutions in risk strategy. Learn more here.
NatureWorks LLC is a Minnetonka, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.
Biorem is a pioneer environmental biotechnology company that designs, manufactures and distributes a comprehensive line of high-efficiency air emissions control systems used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). We offer a selection of products that can be tailored to suit application specific requirements. Biorem ensures optimized long-term performance on every application by custom-designing the solution to meet the individual needs of our clients. With sales and manufacturing offices across the continents, dedicated research facilities, analytical and microbial laboratories, worldwide sales representative network, and a dedicated service division, Biorem has the resources available to ensure that your project is handled promptly and professionally from conception to completion. With the largest installation base of it’s kind in the world, continued extensive research efforts, and over 21 years of experience, Biorem not only offers state of the art technology-based products – but also peace of mind for municipalities, industrial companies and their surrounding communities.
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,400+ employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology medicines: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products in China licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma; and have entered a collaboration with Novartis Pharma AG for Novartis to develop and commercialize tislelizumab in North America, Europe, and Japan.